Michelle Magid
Psychiatry · Austin, TXNPI 1184602591
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Johnson & Johnson accounts for 78.3% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $3,704 and has fallen 95.8% since, to $155 in 2025.
Across 68 payments — averaging $65.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$3K
- AbbVie$259
- Otsuka America Pharmaceutical, Inc.$118
- Neurocrine Biosciences, Inc.$65
- Alfasigma USA, Inc.$61
- Sunovion Pharmaceuticals Inc.$61
- plus $403 from 16 others
What the payments were for
- Speaking & faculty fees$2,25051%
- Travel & lodging$85619%
- Food & beverage$1,34530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 18 | $3,486 |
| AbbVie(2 entities) | 12 | $259 |
| Otsuka America Pharmaceutical, Inc. | 7 | $118 |
| Neurocrine Biosciences, Inc. | 3 | $65 |
| Alfasigma USA, Inc. | 4 | $61 |
| Sunovion Pharmaceuticals Inc. | 3 | $61 |
| Axsome Therapeutics, Inc. | 2 | $41 |
| Shire North American Group Inc | 2 | $40 |
| Bausch Health US, LLC | 1 | $40 |
| Avanir Pharmaceuticals, Inc. | 2 | $39 |
| Corium, LLC | 2 | $37 |
| Alkermes, Inc. | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Lundbeck LLC | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| OWP Pharmaceuticals, Inc. | 1 | $16 |
| Neos Therapeutics, LP | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| Noven Therapeutics, LLC | 1 | $15 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$3,176
How this compares
$4,451 in reported general payments places this provider in the 85th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lisdexamfetamine Dimesylate | 11 | $4,081 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 13 | $4,044 |
| Lurasidone Hcl | 17 | $1,528 |
| Divalproex Sodium ErDivalproex Sodium | 15 | $1,314 |
| Aripiprazole | 19 | $1,281 |
| Lamotrigine | 42 | $715 |
| Quetiapine Fumarate | 42 | $697 |
| Trazodone Hcl | 21 | $507 |
| Bupropion Hcl SrBupropion Hcl | 11 | $491 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 11 | $393 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 18 | $381 |
| Duloxetine Hcl | 25 | $374 |
| Divalproex Sodium | 11 | $302 |
| Clonazepam | 45 | $300 |
| Lithium Carbonate ErLithium Carbonate | 11 | $252 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Austin
- Arvinder Pal WaliaAustin$2.5M
- Charles NemeroffAustin$429K
- Divyansu PatelAustin$50K
- Rakesh JainLake Jackson$7.2M
- Suresh SureddiPlano$2.2M
- Martin GuerreroEl Paso$2M
- Marty BennettAddison$1.8M
- Matthew BramsHouston$1.5M
- Vikram MehraKaty$1.2M
- Joel HolinerDallas$948K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.